NO20025307L - Anvendelse av IL-18 inhibitorer til behandling og/eller forebygging av aterosklerose - Google Patents

Anvendelse av IL-18 inhibitorer til behandling og/eller forebygging av aterosklerose

Info

Publication number
NO20025307L
NO20025307L NO20025307A NO20025307A NO20025307L NO 20025307 L NO20025307 L NO 20025307L NO 20025307 A NO20025307 A NO 20025307A NO 20025307 A NO20025307 A NO 20025307A NO 20025307 L NO20025307 L NO 20025307L
Authority
NO
Norway
Prior art keywords
atherosclerosis
inhibitors
prevention
treatment
Prior art date
Application number
NO20025307A
Other languages
English (en)
Other versions
NO20025307D0 (no
NO329821B1 (no
Inventor
Yolande Chvatchko
Ziad Mallat
Alain Tedgui
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of NO20025307D0 publication Critical patent/NO20025307D0/no
Publication of NO20025307L publication Critical patent/NO20025307L/no
Publication of NO329821B1 publication Critical patent/NO329821B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20025307A 2000-05-05 2002-11-05 Anvendelse av IL-18 inhibitorer, ekspresjonsvektorer som koder for IL-18 inhibitorer og celler genetisk modifisert til a fremstille inhibitorer av IL-18 for fremstilling av medikamenter til behandling og/eller forebygging av aterosklerose, samt anvendelse av IL-18 som diagnostisk markor for progresjon av aterosklerose NO329821B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00109606 2000-05-05
PCT/EP2001/004843 WO2001085201A2 (en) 2000-05-05 2001-04-30 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis

Publications (3)

Publication Number Publication Date
NO20025307D0 NO20025307D0 (no) 2002-11-05
NO20025307L true NO20025307L (no) 2002-12-18
NO329821B1 NO329821B1 (no) 2010-12-27

Family

ID=8168631

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025307A NO329821B1 (no) 2000-05-05 2002-11-05 Anvendelse av IL-18 inhibitorer, ekspresjonsvektorer som koder for IL-18 inhibitorer og celler genetisk modifisert til a fremstille inhibitorer av IL-18 for fremstilling av medikamenter til behandling og/eller forebygging av aterosklerose, samt anvendelse av IL-18 som diagnostisk markor for progresjon av aterosklerose

Country Status (33)

Country Link
US (1) US20040076628A1 (no)
EP (1) EP1278540B1 (no)
JP (1) JP5122053B2 (no)
KR (2) KR20030016254A (no)
CN (2) CN1841066B (no)
AR (1) AR035640A1 (no)
AT (1) ATE395075T1 (no)
AU (2) AU2001267390B2 (no)
BG (1) BG65881B1 (no)
BR (1) BRPI0110506B8 (no)
CA (1) CA2407895C (no)
CY (1) CY1110385T1 (no)
CZ (1) CZ300792B6 (no)
DE (1) DE60134009D1 (no)
DK (1) DK1278540T3 (no)
EA (2) EA005410B1 (no)
EE (1) EE05056B1 (no)
ES (1) ES2305082T3 (no)
HK (2) HK1055681A1 (no)
HR (1) HRP20020828A2 (no)
HU (1) HU229375B1 (no)
IL (2) IL152567A0 (no)
ME (1) ME00554B (no)
MX (1) MXPA02010895A (no)
NO (1) NO329821B1 (no)
PL (1) PL209371B1 (no)
PT (1) PT1278540E (no)
RS (1) RS50926B (no)
SI (1) SI1278540T1 (no)
SK (1) SK287761B6 (no)
UA (2) UA87658C2 (no)
WO (1) WO2001085201A2 (no)
ZA (1) ZA200208228B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520392A (en) * 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
DE60224004T2 (de) * 2001-01-29 2009-07-23 Laboratoires Serono S.A., Coinsins Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
HU230294B1 (hu) 2001-05-25 2015-12-28 Ares Trading S.A. IL-18-inhibitorok alkalmazása központi idegrendszeri sérülések kezelésére vagy megelőzésére
US6797727B2 (en) * 2001-07-16 2004-09-28 Transition Therapeutics Inc. Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
AU2003219162B2 (en) * 2002-03-22 2008-01-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of IL-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases
KR101180139B1 (ko) * 2003-03-11 2012-09-13 메르크 세로노 에스.에이. Ｍｃｍｖ ｉｅ2 프로모터를 포함하는 발현 벡터
JP5074030B2 (ja) 2003-05-13 2012-11-14 メルク セローノ ソシエテ アノニム Ｉｌ−１８結合タンパク質の活性変異体とその医学的応用
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
EP1755642B1 (en) * 2004-04-15 2010-01-13 Athera Biotechnologies Ab Annexin v for preventing plaque rupture
CN101219208B (zh) * 2005-01-04 2010-08-11 健能隆医药技术（上海）有限公司 白介素-22的医药用途
ATE557038T1 (de) 2005-06-03 2012-05-15 Ares Trading Sa Herstellung von rekombinantem il-18 bindendem protein
EP1891088B1 (en) 2005-06-10 2011-10-19 Ares Trading S.A. Process for the purification of il-18 binding protein
TW201215405A (en) 2010-08-25 2012-04-16 Hoffmann La Roche Antibodies against IL-18R1 and uses thereof
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
MD707Z (ro) * 2013-01-18 2014-07-31 Институт Зоологии Академии Наук Молдовы Metodă de identificare a secvenţelor polimorfe 4a/4b ale genei sintetazei endoteliale a oxidului nitric
EP3041864B1 (en) 2013-09-05 2021-07-21 AB2 Bio SA Il-18 binding protein (il-18bp) in inflammatory diseases
AU2016227644B2 (en) 2015-03-05 2022-06-16 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) and antibodies in inflammatory diseases
CN110273591B (zh) 2019-08-13 2023-12-12 上海杉脉电子科技发展有限公司 一种单动力微型智能锁
TW202233675A (zh) 2020-10-29 2022-09-01 瑞士商諾華公司 Ｉｌ－１８拮抗劑用於治療和／或預防異位性皮炎或相關病症之用途
CN112972655A (zh) * 2021-04-16 2021-06-18 武汉大学 白细胞介素12在制备预防、缓解和/或治疗主动脉瘤药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein

Also Published As

Publication number Publication date
AU2001267390B2 (en) 2005-09-22
PL365697A1 (en) 2005-01-10
ZA200208228B (en) 2005-07-27
HK1055681A1 (en) 2004-01-21
CN1250286C (zh) 2006-04-12
NO20025307D0 (no) 2002-11-05
EA200401183A1 (ru) 2004-12-30
PT1278540E (pt) 2008-07-03
EA007014B1 (ru) 2006-06-30
KR20030016254A (ko) 2003-02-26
SK15562002A3 (sk) 2003-05-02
HRP20020828A2 (en) 2004-12-31
MXPA02010895A (es) 2003-03-27
JP5122053B2 (ja) 2013-01-16
AU6739001A (en) 2001-11-20
HUP0301991A3 (en) 2006-11-28
HK1094909A1 (en) 2007-04-13
CY1110385T1 (el) 2015-04-29
BG107218A (bg) 2003-06-30
IL152567A0 (en) 2003-05-29
MEP64008A (en) 2011-12-20
IL152567A (en) 2010-12-30
ES2305082T3 (es) 2008-11-01
RS50926B (sr) 2010-08-31
WO2001085201A3 (en) 2002-05-10
NO329821B1 (no) 2010-12-27
EP1278540A2 (en) 2003-01-29
CA2407895C (en) 2012-12-18
DE60134009D1 (de) 2008-06-26
EA005410B1 (ru) 2005-02-24
WO2001085201A2 (en) 2001-11-15
AR035640A1 (es) 2004-06-23
CZ300792B6 (cs) 2009-08-12
HU229375B1 (en) 2013-11-28
CN1841066A (zh) 2006-10-04
JP2003532685A (ja) 2003-11-05
BRPI0110506B1 (pt) 2015-05-19
KR100798545B1 (ko) 2008-01-28
ME00554B (me) 2012-03-20
BG65881B1 (bg) 2010-04-30
DK1278540T3 (da) 2008-07-21
CZ20023644A3 (cs) 2003-03-12
SK287761B6 (en) 2011-09-05
EE200200620A (et) 2004-06-15
HUP0301991A2 (hu) 2003-09-29
EP1278540B1 (en) 2008-05-14
SI1278540T1 (sl) 2008-10-31
ATE395075T1 (de) 2008-05-15
US20040076628A1 (en) 2004-04-22
UA87658C2 (uk) 2009-08-10
PL209371B1 (pl) 2011-08-31
EA200201175A1 (ru) 2003-04-24
UA78492C2 (en) 2007-04-10
CA2407895A1 (en) 2001-11-15
CN1434722A (zh) 2003-08-06
BRPI0110506B8 (pt) 2021-05-25
EE05056B1 (et) 2008-08-15
KR20070073989A (ko) 2007-07-10
CN1841066B (zh) 2012-08-29
BR0110506A (pt) 2003-04-01
YU82602A (sh) 2006-01-16

Similar Documents

Publication Publication Date Title
NO20025307L (no) Anvendelse av IL-18 inhibitorer til behandling og/eller forebygging av aterosklerose
NO20044195L (no) Biofosfoninsyrer for behandling og prevensjon av osteoprose
NO20032668D0 (no) Gyraseinhibitorer og anvendelser derav
DK1487541T3 (da) Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DK1251848T3 (da) Gyraseinhibitorer og anvendelse deraf
NO20040873L (no) Fremgangsmate og anordning for sammensetting av gjenfestbare absorberende klesplagg
FI20011417A (fi) Menetelmä suojata elektroninen laite ja elektroninen laite
NO20030725D0 (no) Terapeutisk kombinasjon av CETP-inhibitor og atorvastatin
NO20015274D0 (no) ACE-2 inhiberende forbindelser og fremgangsmåter for anvendelse derav
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
NO20022656L (no) Caspaseinhibitorer og anvendelse derav
NO20041004L (no) Fremgangsmate og anordning for sammensetting av gjenfestbare absorberende klesplagg
NO20033854L (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
NO20031806D0 (no) Anvendelse av pericytt apoptosehemmere for behandling og/eller forhindringav diabetisk retinopati
NO20033228D0 (no) Anvendelse av IL-18 inhibitorer til behandling og/eller forhindring av hjertesykdom
PT1274700E (pt) Di-hidrobenzopiranos di-hidrobenzotiopiranos e tetra-hidroquinolinas para o tratamento de afeccoes mediadas por cox-2
NO20023737L (no) Fremgangsmåte og preparater for behandling av en inflammatorisk lidelse
EE05263B1 (et) IL-18 inhibiitorite kasutamine keskn„rvissteemi kahjustuste raviks v?i ennetamiseks
IS6707A (is) Efnablanda til forvarna og meðhöndlunar á krabbameini
NO20035299D0 (no) Preparater og syklooksygenase-2-selektive inhibitorer og bestråling for inhibering eller forhindring av kardiovaskul¶re sykdommer
NO20011176D0 (no) FremgangsmÕte og anordning ved mær
DK1307761T3 (da) Fremgangsmåde til retningsbestemmelse og bestemmelsesapparat
NO20040177L (no) Karbamatforbindelser for bruk til forebyggelse eller behandling av neuropatisk smerte og kluster- og migrenehodepineassosiert smerte
NO20051879D0 (no) Anvendelse av proteintyrosinfosfataseinhibitorer til forhindring og/eller behandling av kreft

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

MK1K Patent expired